AIMS: To characterize the relationship between advanced glycation end products (AGEs) and circulating receptors for AGEs (RAGE) with cardiovascular disease mortality. METHODS: The relationships between serum AGEs, total RAGE (sRAGE), and endogenous secretory RAGE (esRAGE), and mortality were characterized in 559 community-dwelling women, double dagger 65 years, in Baltimore, Maryland. RESULTS: During 4.5 years of follow-up, 123 (22%) women died, of whom 54 died with cardiovascular disease. The measure of serum AGEs was carboxymethyl-lysine (CML), a dominant AGE. Serum CML predicted cardiovascular disease mortality (Hazards Ratio [HR] for highest vs lower three quartiles, 1.94, 95% Confidence Interval [CI] 1.08-3.48, p=0.026), after adjusting for age, race, body mass index, and renal insufficiency. Serum sRAGE (ng/mL) and esRAGE (ng/mL) predicted cardiovascular disease mortality (HR per 1 Standard Deviation [SD] 1.27, 95% CI 0.98-1.65, p=0.07; HR 1.28, 95% CI 1.02-1.63, p=0.03), after adjusting for the same covariates. Among non-diabetic women, serum CML, sRAGE, and esRAGE, respectively, predicted cardiovascular disease mortality (HR for highest vs lower three quartiles, 2.29, 95% CI 1.21-4.34, p=0.01; HR per 1 SD, 1.24, 95% CI 0.92-1.65, p=0.16; HR per 1 SD 1.45, 95% CI 1.08-1.93, p=0.01), after adjusting for the same covariates. CONCLUSIONS: High circulating AGEs and RAGE predict cardiovascular disease mortality among older community-dwelling women. AGEs are a potential target for interventions, as serum AGEs can be lowered by change in dietary pattern and pharmacological treatment.
AIMS: To characterize the relationship between advanced glycation end products (AGEs) and circulating receptors for AGEs (RAGE) with cardiovascular disease mortality. METHODS: The relationships between serum AGEs, total RAGE (sRAGE), and endogenous secretory RAGE (esRAGE), and mortality were characterized in 559 community-dwelling women, double dagger 65 years, in Baltimore, Maryland. RESULTS: During 4.5 years of follow-up, 123 (22%) women died, of whom 54 died with cardiovascular disease. The measure of serum AGEs was carboxymethyl-lysine (CML), a dominant AGE. Serum CML predicted cardiovascular disease mortality (Hazards Ratio [HR] for highest vs lower three quartiles, 1.94, 95% Confidence Interval [CI] 1.08-3.48, p=0.026), after adjusting for age, race, body mass index, and renal insufficiency. Serum sRAGE (ng/mL) and esRAGE (ng/mL) predicted cardiovascular disease mortality (HR per 1 Standard Deviation [SD] 1.27, 95% CI 0.98-1.65, p=0.07; HR 1.28, 95% CI 1.02-1.63, p=0.03), after adjusting for the same covariates. Among non-diabeticwomen, serum CML, sRAGE, and esRAGE, respectively, predicted cardiovascular disease mortality (HR for highest vs lower three quartiles, 2.29, 95% CI 1.21-4.34, p=0.01; HR per 1 SD, 1.24, 95% CI 0.92-1.65, p=0.16; HR per 1 SD 1.45, 95% CI 1.08-1.93, p=0.01), after adjusting for the same covariates. CONCLUSIONS: High circulating AGEs and RAGE predict cardiovascular disease mortality among older community-dwelling women. AGEs are a potential target for interventions, as serum AGEs can be lowered by change in dietary pattern and pharmacological treatment.
Authors: D A Kass; E P Shapiro; M Kawaguchi; A R Capriotti; A Scuteri; R C deGroof; E G Lakatta Journal: Circulation Date: 2001-09-25 Impact factor: 29.690
Authors: Heather E Whitson; Alice M Arnold; Laura M Yee; Kenneth J Mukamal; Jorge R Kizer; Luc Djousse; Joachim H Ix; David Siscovick; Russell P Tracy; Stephen M Thielke; Calvin Hirsch; Anne B Newman; Susan Zieman Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-14 Impact factor: 6.053
Authors: Richard D Semba; Sarah K Gebauer; David J Baer; Kai Sun; Randi Turner; Harry A Silber; Sameera Talegawkar; Luigi Ferrucci; Janet A Novotny Journal: J Nutr Date: 2014-04-17 Impact factor: 4.798
Authors: Candace L Crasto; Richard D Semba; Kai Sun; Mansi Dalal; Anna Maria Corsi; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2011-02-28 Impact factor: 6.053
Authors: V C Luft; B B Duncan; M I Schmidt; L E Chambless; J S Pankow; R C Hoogeveen; D J Couper; G Heiss Journal: Diabet Med Date: 2015-10-06 Impact factor: 4.359
Authors: R D Semba; A Ang; S Talegawkar; C Crasto; M Dalal; P Jardack; M G Traber; L Ferrucci; L Arab Journal: Eur J Clin Nutr Date: 2011-07-27 Impact factor: 4.016
Authors: Richard D Semba; Stefania Bandinelli; Kai Sun; Jack M Guralnik; Luigi Ferrucci Journal: Eur J Appl Physiol Date: 2009-09-16 Impact factor: 3.078
Authors: Jorge R Kizer; David Benkeser; Alice M Arnold; Joachim H Ix; Kenneth J Mukamal; Luc Djousse; Russell P Tracy; David S Siscovick; Bruce M Psaty; Susan J Zieman Journal: Atherosclerosis Date: 2014-04-30 Impact factor: 5.162
Authors: Mariana Lazo; Marc K Halushka; Lu Shen; Nisa Maruthur; Casey M Rebholz; Andreea M Rawlings; Ron C Hoogeveen; Tina E Brinkley; Christie M Ballantyne; Brad C Astor; Elizabeth Selvin Journal: Am Heart J Date: 2015-08-14 Impact factor: 4.749